• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Curis Inc.

    4/15/24 2:12:19 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email
    SC 13G 1 d11024085_13g.htm

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

    Curis, Inc.
    (Name of Issuer)

     

     

    Common Stock, Par Value $0.01 per share
    (Title of Class of Securities)

     

     

    231269309
    (CUSIP Number)

     

     

    April 4, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [_] Rule 13d-1(d)

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 231269309    

     

    1. NAME OF REPORTING PERSONS  
         
      Kingdon Capital Management, L.L.C.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      345,730  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      345,730  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      345,730  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA  

     

     
     

     

    CUSIP No 231269309    

     

    1. NAME OF REPORTING PERSONS  
         
      M. Kingdon Offshore Master Fund L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      311,157  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      311,157  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      311,157  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  

     

     
     

     

    CUSIP No 231269309    

     

    1. NAME OF REPORTING PERSONS  
         
      Kingdon GP, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      311,157  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      311,157  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      311,157  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      OO  

     

     
     

     

    CUSIP No 231269309    

     

    1. NAME OF REPORTING PERSONS  
         
      Mark Kingdon  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      345,730  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      345,730  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      345,730  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  

     

     
     

     

    CUSIP No 231269309    

     

    Item 1. (a) Name of Issuer:  
           
        Curis, Inc.  
       

     

     

     
      (b) Address of Issuer's Principal Executive Offices:  
           
       

    128 Spring Street

    Building C – Suite 500

    Lexington, Massachusetts 02421

    United States of America

     
           
    Item 2. (a) Name of Person Filing:  
           
       

    Kingdon Capital Management, L.L.C.

    M. Kingdon Offshore Master Fund L.P.

    Kingdon GP, LLC

    Mark Kingdon

     
           
      (b) Address of Principal Business Office, or if None, Residence:  
           
       

    Kingdon Capital Management, L.L.C.

    152 West 57th Street, 50th Floor
    New York, New York 10019
    United States of America

    M. Kingdon Offshore Master Fund L.P.

    c/o Kingdon Capital Management, L.L.C.
    152 West 57th Street, 50th Floor
    New York, New York 10019
    United States of America

    Kingdon GP, LLC

    c/o Kingdon Capital Management, L.L.C.
    152 West 57th Street, 50th Floor
    New York, New York 10019
    United States of America

    Mark Kingdon

    c/o Kingdon Capital Management, L.L.C.
    152 West 57th Street, 50th Floor
    New York, New York 10019
    United States of America

     

     

      (c) Citizenship:  
           
       

    Kingdon Capital Management, L.L.C. – Delaware

    M. Kingdon Offshore Master Fund L.P. – Cayman Islands

    Kingdon GP, LLC – Delaware

    Mark Kingdon – United States of America

     
           
     
     

     

      (d) Title of Class of Securities:  
           
        Common Stock, Par Value $0.01 per share  
           
      (e) CUSIP Number:  
           
        231269309  
       

     

     


    Item 3.
      If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         
      (a) [_] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [_]

    A non-U.S. institution in accordance with s.240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with s.240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

      (k) [_]

    Group, in accordance with s.240.13d-1(b)(1)(ii)(K).

     

             

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
         
     
     

     

       

    Kingdon Capital Management, L.L.C. – 345,730

    M. Kingdon Offshore Master Fund L.P. – 311,157

    Kingdon GP, LLC – 311,157

    Mark Kingdon – 345,730

       

     

     

      (b) Percent of class:
         
       

    Kingdon Capital Management, L.L.C. – 5.9%

    M. Kingdon Offshore Master Fund L.P. – 5.3%

    Kingdon GP, LLC – 5.3%

    Mark Kingdon – 5.9%

         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote
         

     

    Kingdon Capital Management, L.L.C. – 0

    M. Kingdon Offshore Master Fund L.P. – 0

    Kingdon GP, LLC – 0

    Mark Kingdon – 0

           
        (ii) Shared power to vote or to direct the vote
         

     

    Kingdon Capital Management, L.L.C. – 345,730

    M. Kingdon Offshore Master Fund L.P. – 311,157

    Kingdon GP, LLC – 311,157

    Mark Kingdon – 345,730

           
        (iii) Sole power to dispose or to direct the disposition of
         

     

    Kingdon Capital Management, L.L.C. – 0

    M. Kingdon Offshore Master Fund L.P. – 0

    Kingdon GP, LLC – 0

    Mark Kingdon – 0

           
        (iv) Shared power to dispose or to direct the disposition of
         

     

    Kingdon Capital Management, L.L.C. – 345,730

    M. Kingdon Offshore Master Fund L.P. – 311,157

    Kingdon GP, LLC – 311,157

    Mark Kingdon – 345,730

     

     

    Item 5. Ownership of 5 Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [_].
     
      N/A

     

     

     
     
     

     

    Item 6. Ownership of More Than 5 Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      All of the securities reported in this Schedule 13G are directly owned by advisory clients of Kingdon Capital Management, L.L.C.  None of those advisory clients, other than M. Kingdon Offshore Master Fund L.P., may be deemed to beneficially own more than 5% of the Common Stock, Par Value $0.01 per share.

     

     

     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Please see Exhibit B attached hereto.

     

     

     

    Item 8.
    Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A

     

     

     
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A

     

     

     
     

     

    Item 10. Certification.
     
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
         
     
     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      April 15, 2024
      (Date)

     

      KINGDON CAPITAL MANAGEMENT, L.L.C.*
         
      By: /s/ William Walsh
        Name:  William Walsh
        Title:  Chief Financial Officer
         
         
     

    M. KINGDON OFFSHORE MASTER FUND L.P.*

    By: Kingdon GP, LLC, its general partner 

         
      By: /s/ Mark Kingdon
        Name:  Mark Kingdon
        Title:  Managing Member
         
         
      KINGDON GP, LLC*
         
      By: /s/ Mark Kingdon
        Name:  Mark Kingdon
        Title: Managing Member
         
         
      MARK KINGDON*
         
      By: /s/ Mark Kingdon
        Mark Kingdon

     

     

    * This Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated April 15, 2024 relating to the Common Stock, Par Value $0.01 per share of Curis, Inc. shall be filed on behalf of the undersigned.

      KINGDON CAPITAL MANAGEMENT, L.L.C.
         
      By: /s/ s/ William Walsh
        Name:William Walsh
        Title: Chief Financial Officer
         
         
     

    M. KINGDON OFFSHORE MASTER FUND L.P.

    By: Kingdon GP, LLC, its general partner 

         
      By: /s/ Mark Kingdon
        Name: Mark Kingdon
        Title: Managing Member
         
         
      KINGDON GP, LLC
         
      By: /s/Mark Kingdon
        Name: Mark Kingdon
        Title: Managing Member
         
         
      MARK KINGDON
         
      By: /s/ Mark Kingdon
        Mark Kingdon

     

     

     
     

     

    Exhibit B

    Kingdon Capital Management, L.L.C. is the relevant entity for which Mark Kingdon may be considered a control person.

     

     

     

     

    Get the next $CRIS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    Financials

    Live finance-specific insights

    See more
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

      LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

      3/28/25 4:07:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

      LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

      11/7/24 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant"). The Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock

      5/6/25 6:16:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Provides First Quarter 2025 Business Update

      Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025. "I am pleased to announce the expansion of the Curis Executive Team with the addition of Dr. Ahmed Hamdy as

      5/6/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Curis Inc.

      10-Q - CURIS INC (0001108205) (Filer)

      5/6/25 8:04:49 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CURIS INC (0001108205) (Filer)

      5/6/25 8:03:06 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Curis Inc.

      DEFA14A - CURIS INC (0001108205) (Filer)

      4/10/25 4:27:59 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO Hamdy Ahmed Md

      4 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:26:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Hamdy Ahmed Md

      3 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:24:56 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Duvall Diantha

      4 - CURIS INC (0001108205) (Issuer)

      1/30/25 4:11:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Curis with a new price target

      H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

      5/19/25 8:52:11 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Truist initiated coverage on Curis with a new price target

      Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

      11/17/23 7:37:50 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis downgraded by Raymond James

      Raymond James downgraded Curis from Outperform to Mkt Perform

      4/4/22 11:27:43 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    See more
    • Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

      LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

      1/3/22 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Appoints John A. Hohneker, M.D. To Board Of Directors

      LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

      12/6/21 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

      1/8/21 4:01:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Curis Inc.

      SC 13G/A - CURIS INC (0001108205) (Subject)

      11/13/24 2:05:06 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      11/1/24 4:35:37 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      4/15/24 2:12:19 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care